None listed
Conditions
Brief summary
This study aims to determine whether ultrasound evidence of urate crystal deposition is a necessary precondition for the development of gout and to understand the pathological mechanisms responsible for the transition from asymptomatic crystal deposition to gout. This five year prospective study, led from Auckland, New Zealand, will involve the recruitment of over 900 participants across multiple international sites. Eligible participants will attend a baseline study visit which will include recording of demographic information, a physical exam, assessment of clinical risk factors, and assessment of health related quality of life, activity limitations, illness perception and pain. Whole blood, serum and urine samples will be collected for biochemical and genetic testing. Bilateral radiographs of the feet will be obtained and an ultrasound assessment of the feet and knees will be performed to assess for crystal deposition, bone erosion and features of soft tissue inflammation. Participants will be followed up six-monthly to determine whether they have developed symptoms of new joint pain or swelling. Participants will attend a second visit after 5 years, or earlier if they develop gout, where these outcomes will be re-assessed.
Interventions
This is a prospective cohort study of people with asymptomatic hyperuricemia. Participants will attend a baseline study visit where clinical data will be collected, blood samples will be obtained, and an ultrasound scan performed. Participants will then be followed for 5 years to identify factors associated with the development of symptomatic gout. During the 5 year follow-up period participants will be contacted every 6 months to assess gout development. If participants develop gout during the
This is a prospective cohort study of people with asymptomatic hyperuricemia. Participants will attend a baseline study visit where clinical data will be collected, blood samples will be obtained, and an ultrasound scan performed. Participants will then be followed for 5 years to identify factors associated with the development of symptomatic gout. During the 5 year follow-up period participants will be contacted every 6 months to assess gout development. If participants develop gout during the 5 year follow-up period they will attend a second study visit, where the baseline assessments will be repeated. If participants do not develop gout, they will continue in the study and attend a final study visit at 5 years where the baseline assessments will be repeated.
Sponsors
The University of Auckland
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Current serum urate level of greater than or equal to 8 mg/dl 2. No current or previous clinical symptoms of gout (including flares or clinically apparent tophi) 3. Able to provide informed consent, according to requirements of local IRB/ethics committee
Exclusion criteria
1. eGRF < 30 mL/min/1.73 m² or on renal replacement therapy 2. Serious illness with poor prognosis less than 5 years 3. Plans to shift out of area in the next 5 years 4. Previous synovial fluid analysis showing MSU crystals 5. The presence of subcutaneous tophi 6. Taking urate lowering therapy (e.g. allopurinol, probenecid, benzbromarone, febuxostat), canakinumab, or colchicine.
Outcome results
None listed